IPSEN, OOO

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: -

Established: 1929-01-01

Employees: 5.7K

Market Cap: $9.8B

Website: https://www.ipsen.com/

Clinical Trials

Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Elafibranor

First Posted Date: 2022-09-16

Last Posted Date: 2023-07-18

Lead Sponsor: Ipsen

Target Recruit Count: 48

Registration Number: NCT05543369

Locations: 🇺🇸
Collaborative Neuroscience Research LLC, Long Beach, California, United States
🇺🇸
Collaborative Neuroscience Research, LLC, Los Alamitos, California, United States

Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Triptorelin embonate 22.5 mg

First Posted Date: 2022-07-14

Last Posted Date: 2024-08-01

Lead Sponsor: Ipsen

Target Recruit Count: 147

Registration Number: NCT05458856

Locations: 🇧🇪
Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
🇧🇪
UZ Antwerpen, Edegem, Belgium
🇧🇪
CHU de Liège - Domaine Universitaire du Sart Tilman - Urologie, Liège, Belgium

and more 36 locations

A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.

Completed

Conditions: Advanced Renal Cell Carcinoma

First Posted Date: 2022-07-06

Last Posted Date: 2023-07-18

Lead Sponsor: Ipsen

Target Recruit Count: 252

Registration Number: NCT05444933

Locations: 🇫🇷
CHU Besançon, Besançon, France
🇫🇷
Hôpital Edouard Herriot, Lyon, France
🇫🇷
CHU Amiens, Amiens, France

and more 24 locations

Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

Active, not recruiting

Conditions: Acromegaly

First Posted Date: 2022-06-24

Last Posted Date: 2024-12-02

Lead Sponsor: Ipsen

Target Recruit Count: 129

Registration Number: NCT05431803

Locations: 🇨🇳
The First Affiliated Hospital,Sun Yat-sen University (FAHSYSU), Guangzhou, China
🇨🇳
The Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU), Hangzhou, China
🇨🇳
The First Hospital of China Medical University (CMU1H), Shenyang, China

and more 9 locations

A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas

Phase 1

Active, not recruiting

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: Irinotecan liposome injection
Drug: Folinic Acid
Drug: 5-Fluorouracil

First Posted Date: 2022-05-20

Last Posted Date: 2024-12-02

Lead Sponsor: Ipsen

Target Recruit Count: 177

Registration Number: NCT05383352

Locations: 🇫🇷
Institut BERGONIE Centre de Lutte Contre le Cancer, Bordeaux, France
🇦🇺
Flinders Medical Centre, Bedford Park, Australia
🇦🇺
Peninsula and Southeast Oncology - Frankston Private Hospital, Frankston, Australia

and more 33 locations

Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment

Recruiting

Conditions: Early-stage Breast Cancer

First Posted Date: 2022-05-17

Last Posted Date: 2024-11-01

Lead Sponsor: Ipsen

Target Recruit Count: 419

Registration Number: NCT05377684

Locations: 🇮🇹
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
🇮🇹
Ospedale S. Gerardo, Monza, Italy
🇮🇹
Policlinico S. Orsola - Malpighi, Bologna, Italy

and more 19 locations

A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults

Active, not recruiting

Conditions: Advanced Renal Cell Carcinoma

First Posted Date: 2022-05-04

Last Posted Date: 2024-11-01

Lead Sponsor: Ipsen

Target Recruit Count: 311

Registration Number: NCT05361434

Locations: 🇧🇪
CHU St Pierre & Brugmann, Bruxelles, Belgium
🇧🇪
Jessa Ziekenhuis, Hasselt, Belgium
🇧🇪
CHU Namur Mont-Godinne, Yvoir, Belgium

and more 63 locations

Effectiveness and Safety of SMART [Spastic Muscle Palpation by Anatomic Landscape for BoNT-A (Botulinumtoxin-A) Injection to Reduce Muscle Tone] BoNT-A Therapy With Dysport® in Patients With Post-stroke Chronic Upper Limb Spasticity (ULS) in Real-life Setting.

Recruiting

Conditions: Post-Stroke Chronic Upper Limb Spasticity

First Posted Date: 2022-02-04

Last Posted Date: 2024-11-26

Lead Sponsor: Ipsen

Target Recruit Count: 116

Registration Number: NCT05224349

Locations: 🇩🇪
Neuropraxis Fürth, Fürth, Germany
🇩🇪
Gemeinschaftspraxis, Straubing, Germany
🇩🇪
Nervenarztpraxis, Altdorf, Germany

and more 27 locations

Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China

Withdrawn

Conditions: Acromegaly

First Posted Date: 2022-01-11

Last Posted Date: 2023-03-17

Lead Sponsor: Ipsen

Registration Number: NCT05184231

A Single Centre, Prospective, Observational Study to Assess the Use of the Rehabilitation Tool, GripAble, in Patients With Upper Limb Spasticity Receiving Botulinum Toxin-A (BoNT-A) in the United Kingdom (UK).

Completed

Conditions: Upper Limb Spasticity (ULS)

First Posted Date: 2021-12-27

Last Posted Date: 2023-01-27

Lead Sponsor: Ipsen

Target Recruit Count: 16

Registration Number: NCT05169775

Locations: 🇬🇧
Hull University Teaching Hospital NHS Trust, Hull, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy